yeah but doesn’t that still leave the problem of having to compete with generics? Was this overlooked by BG and team, or was there always a (secret) plan to reformulate?
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-17
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.065(4.05%) |
Mkt cap ! $262.4M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.51 | $261.3K | 168.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |